<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044065</url>
  </required_header>
  <id_info>
    <org_study_id>PREV-Ex</org_study_id>
    <nct_id>NCT05044065</nct_id>
  </id_info>
  <brief_title>Metabolic Stress-induced Exercise to Prevent Loss of Muscle Mass in Patients With Pancreatic and Biliary Tract Cancer</brief_title>
  <acronym>PREV-Ex</acronym>
  <official_title>Metabolic Stress-induced Exercise in the Perioperative Setting to Prevent the Loss of Muscle Mass in Patients With Pancreatic and Biliary Tract Cancer - the PREV-Ex Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian School of Sport Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with cancer, resistance training appears to be a safe and effective exercise&#xD;
      modality to increase both lean muscle mass and strength, as well as attenuates cancer-related&#xD;
      fatigue. It may serve as a feasible intervention in these patients to mitigate cachexia,&#xD;
      especially if implemented before the onset of cancer cachexia or in a pre-cachectic state.&#xD;
      This study is a multicenter randomized controlled trial that will compare a metabolic-stress&#xD;
      induced resistance training intervention during the pre- (prehabilitation) and post-operative&#xD;
      (rehabilitation) phase in patients with pancreatic and biliary tract cancer, versus usual&#xD;
      care on skeletal muscle and other health-related outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 14, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal muscle thickness</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Skeletal muscle thickness (mm) measured through ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal muscle cross sectional area</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Skeletal muscle cross sectional area (um2) measured through ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle morphology</measure>
    <time_frame>Change from baseline to: 2 weeks, 8 weeks</time_frame>
    <description>Skeletal muscle morphology (au) measured through microscopy methods in skeletal muscle biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle protein levels</measure>
    <time_frame>Change from baseline to: 2 weeks, 8 weeks</time_frame>
    <description>Skeletal muscle protein levels (au) measured through western blot in skeletal muscle biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle metabolism</measure>
    <time_frame>Change from baseline to: 2 weeks, 8 weeks</time_frame>
    <description>Skeletal muscle metabolism (au) measured through biochemical methods in skeletal muscle biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body lean mass</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Lean mass (kg) measured through bioimpedance and CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat mass</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Fat mass (kg) measured through bioimpedance and CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip strength</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Maximal handgrip strength (kg) measured through hand dynamometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower limb muscle strength</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Maximal led strength (kg) measured through isometric force measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Disease specific helath related quality of life measured with The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC-QLQ-C30) Summary Score (0-100 points with a higher score indicating a better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical performance</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Short Physical Performance Battery (SPPB score points ranging from 0-12 with a higher score indicating a better physical function) measured through handgrip strength test, leg strength test, endurance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-related fatigue</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Fatigue12 (EORTC-QLQ-FA12) Summary Score (0-100 points with a higher score indicating a better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Subjective Global Assessment Form scores (score ranging between 7 (normal) and 35 (severely malnourished)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' experience of the exercise program</measure>
    <time_frame>8 weeks</time_frame>
    <description>Focus group interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related complications</measure>
    <time_frame>4 weeks</time_frame>
    <description>days to recover after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related complications</measure>
    <time_frame>8 weeks</time_frame>
    <description>days to recover after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related complications</measure>
    <time_frame>16 weeks</time_frame>
    <description>days to recover after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>4 weeks</time_frame>
    <description>days of being hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>8 weeks</time_frame>
    <description>days of being hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>16 weeks</time_frame>
    <description>days of being hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Measured through an activity tracker (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Diastolic blood pressure (mmHg) measured at rest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Systolic blood pressure (mmHg) measured at rest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Change from baseline to: 2 weeks, 4 weeks, 8 weeks, 16 weeks</time_frame>
    <description>Measured through the passive leg movement (PLM) technique through ultrasound measurements (blood flow in mL/min)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Exercise group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will in addition to standard care receive supervised and home-based exercise training program with a specific focus to induce metabolic stress, and protein supplementation to ensure adequate protein intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will in addition to standard care receive protein supplementation to ensure adequate protein intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical exercise</intervention_name>
    <description>The intervention group will receive an exercise program consisting of a combination of supervised and home-based exercise with a focus to induce metabolic stress during both a pre- and postoperative period consisting of a total of 5-6 weeks. Protein supplementation will be given to exclude insufficient intake.</description>
    <arm_group_label>Exercise group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of resectable pancreatic cancer&#xD;
&#xD;
          -  Diagnosis of resectable biliary tract cancer (includes cholangiocarcinoma and&#xD;
             ampullary cancer)&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group scale) performance status â‰¤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious active infection&#xD;
&#xD;
          -  Uncontrolled severe pain&#xD;
&#xD;
          -  Severe neurologic or cardiac impairment according ACSM criteria&#xD;
&#xD;
          -  Uncontrolled severe respiratory insufficiency as determined by the treating clinician&#xD;
&#xD;
          -  Any other contraindications for exercise as determined by the treating physician&#xD;
&#xD;
          -  Poor Swedish comprehension&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Mijwel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Mijwel, PhD</last_name>
    <phone>+46761625352</phone>
    <email>sara.mijwel@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hopsital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara Mijwel, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Sara Mijwel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

